Targeted Long-Acting Combination Antiretroviral Therapy Program (TLC-ART)

Targeted Long Acting HIV Therapy intended to clear virus in tissues and cells

Click here to visit the TLC-ART website.

Welcome to the University of Washington Targeted Long-acting Combination Anti-Retroviral Therapy (TLC-ART) program. We are scientists and physicians working toward developing a long acting and effective treatment to improve patient compliance and therapeutic outcomes. We hope to maximally suppress HIV and potentially contribute to a cure for AIDS.

Our researchers were the first to document pharmacological drug deficiency with HIV oral treatment. This has been linked to residual HIV in tissues. The TLC-ART program intends to overcome pharmacological drug deficiency by developing long-lasting, potent, antiretroviral therapies.

Contact Information

TLCART Program Coordinator
Jonathan Sallows
UWMC H-Wing rm H115
Box 357610
1959 NE Pacific St.
Health Sciences Building
Seattle, WA 98195
Phone: (206) 543-8769
Fax: (206) 543-3204

or e-mail tlcart@uw.edu directly

Principle Investigator: Dr. Rodney JY Ho, PhD, FAAAS, FAAPS